Search IPOs
SUDEEPPHRM · NSE,BSE · Specialty Chemicals
Sudeep Pharma IPO listed on 28 Nov 2025 on NSE,BSE at ₹730.00, a gain of 23.10% over the issue price of ₹593.00. The IPO was subscribed 93.72x overall.
Sudeep Pharma IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 21 Nov 2025 |
| IPO Close Date | 25 Nov 2025 |
| Basis of Allotment | 26 Nov 2025 |
| Initiation of Refunds | 27 Nov 2025 |
| Credit of Shares to Demat | 27 Nov 2025 |
| Listing Date | 28 Nov 2025 |
Listing day gain
+23.1%
Listed at ₹730 (issue ₹593)
Issue
₹593
Listing
₹730
Current
₹774.15
+30.55% vs issue
Day range
₹725 – ₹795
Issue Size
15,092,749 shares
(aggregating up to ₹895.00 Cr)
Issue Price
₹563 – ₹593
Face Value
₹1/share
Market Lot
25 shares
Retail Min Investment
₹14,825
Listing At
NSE,BSE
Sale Type
both
Fresh Issue
1,602,023 shares
(aggregating up to ₹95 Cr)
Offer for Sale
13,490,726 shares
(aggregating up to ₹800 Cr)
Issue Type
book building
Open Date
21 Nov
Close Date
25 Nov
Allotment
26 Nov
Listing
28 Nov
Last updated: 10 months ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 28 Nov 2025 Latest | ₹593 | ₹121 | ₹714 | ₹121 |
20.4%
|
12:00 AM |
| 27 Nov 2025 | ₹593 | ₹121 | ₹714 | ₹121 |
20.4%
|
12:00 AM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 28 Nov 2025
| Category | Subscribed (x) |
|---|---|
| QIB | 213.08x |
| NII | 116.72x |
| bNII (bids above ₹10L) | 134.91x |
| sNII (bids below ₹10L) | 80.33x |
| Retail Investors | 15.65x |
| Total | 93.72x |
Showing the latest subscription snapshot.
View full subscription historySujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani (HUF), Riva Resources Pvt.Ltd. and Bhayani Family Trust are the promoters of the company.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹192,725 |
| S-HNI (Min) | 14 | 350 | ₹207,550 |
| S-HNI (Max) | 67 | 1,675 | ₹993,275 |
| B-HNI (Min) | 68 | 1,700 | ₹1,008,100 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 7,546,373 (50.00%) |
|
•
Anchor Investor Shares Offered
|
4,527,823 (30.00%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
3,018,550 (20.00%) |
| NII (HNI) Shares Offered | 2,263,913 (15.00%) |
|
•
bNII > ₹10L
|
1,509,276 (10.00%) |
|
•
sNII < ₹10L
|
754,637 (5.00%) |
| Retail Shares Offered | 5,282,463 (35.00%) |
| Total Shares Offered | 15,092,749 (100.00%) |
Sudeep Pharma Limited was incorporated in December 1989 and is headquartered in Vadodara, Gujarat. It works in the specialty chemicals sector, manufacturing excipients and mineral-based specialty ingredients.
The company manufactures pharmaceutical excipients, food-grade minerals and specialty nutrition ingredients such as calcium, iron, magnesium, zinc, potassium and sodium compounds, supplying over 100 products to customers in more than 100 countries. It operates four manufacturing facilities in Vadodara, with an additional facility being commissioned at Nandesari, and holds accreditations including USFDA, WHO-GMP and ISO certifications. Its customers span the pharmaceutical, food and nutrition industries, with exports accounting for a majority of revenue in recent years. The company also holds an 85% stake in Nutrition Supply and Services (Ireland) Limited. The promoters include Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF and Riva Resources Private Limited.
Revenue from operations was Rs 501.99 crore in FY25, up from Rs 459.28 crore in FY24, with profit after tax of Rs 138.69 crore in FY25, as per the RHP. The IPO was a mainboard book-built issue on the NSE and BSE, comprising a fresh issue of Rs 95 crore and an offer for sale of Rs 800 crore by promoter selling shareholders, and it listed on 28 November 2025. Net proceeds from the fresh issue were earmarked for capital expenditure on machinery for the Nandesari Facility I production line (about Rs 75.81 crore) and general corporate purposes.
Standalone · ₹ in Crores
| Particulars | FY Mar 2023 | FY Mar 2024 | FY Mar 2025 |
|---|---|---|---|
| Total Revenue | 438.26 | 465.38 | 130.08 |
| Profit After Tax (PAT) | 62.32 | 133.15 | 31.27 |
| EBITDA | 98.64 | 187.76 | 48.57 |
| Total Assets | 420.11 | 513.87 | 922.26 |
| Net Worth | 226.29 | 359.07 | 688.32 |
| Reserves & Surplus | 221.88 | 354.59 | 668.52 |
| Total Borrowing | 82.26 | 75.03 | 135.97 |
Revenue & Profit Trend
Key ratios per fiscal period
| Particulars | Mar 2025 |
|---|---|
| RoNW Return on Net Worth Shows the profit earned on the company's own net worth. Steady or rising over 3 years is a good sign. | 27.88% |
| PAT Margin Profit After Tax Margin Out of every ₹100 of sales, how much the company keeps after paying all costs, loan interest and tax. | 27.63% |
| EBITDA Margin Earnings Before Interest, Tax, Depreciation and Amortisation Margin Profit from the main business as a share of sales, before loan interest and tax. Compare it with other companies in the same industry. | 39.7% |
| Debt / Equity Debt to Equity How much the company has borrowed against what shareholders own. Above 1x means the loans are bigger than shareholder funds. | 0.2x |
| P/BV Price to Book Value Tells you if the IPO price is above what the company actually owns. 1x to 3x is usually seen as reasonable. | 12.93x |
Issue-level · at the upper price band
| Particulars | Pre-IPO | Post-IPO |
|---|---|---|
| EPS Earnings Per Share Profit the company earns on each share. Post-IPO EPS is usually lower because the issue adds new shares. | ₹12.46 | ₹11.07 |
| P/E Price to Earnings Tells you if the IPO price is fair for what the company earns. Compare it with listed companies in the same sector. | 47.61x | 53.55x |
| Market Cap Market Capitalisation What the whole company is valued at, at the upper price band. Post-IPO counts the new shares the issue creates. | ₹6,603 Cr | ₹8,744 Cr |
The basis of allotment for Sudeep Pharma IPO was finalised on 26 Nov 2025. You can check your allotment status using your PAN number or application number on the MUFG Intime India Pvt.Ltd portal or BSE.
The Sudeep Pharma IPO is expected to open in Nov 2025, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Sudeep Pharma IPO is ₹563.00 - ₹593.00 per share.
As per market sources, Sudeep Pharma IPO GMP is currently ₹121.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Sudeep Pharma IPO stands at 93.72x overall.
The listing date for Sudeep Pharma IPO is 28 Nov 2025.
No comments yet. Be the first to comment!
